The statement also noted that in controlled clinical trials of metastatic breast cancer, the additional administration of bevacizumab only led to significantly increased progression-free survival but, to date, did not result in any increase in overall survival, while at the same time the potential toxicity was quite significant 18 , 19 , 20 .
← all excerpts
ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results.
1
—
—